JS207
JS207 is a humanized IgG4-specific antibody targeting PD-1 and VEGFA. JS207 can block PD-1/PD-L1, PD-1/PD-L2, and VEGFA/VEGFR2 interactions, with IC50 values of 6.37 nM, 4.3 nM, and 3.35 nM, respectively. JS207 can relieve immunosuppression, promote T cell activation and IL-2/IFN-γ release, and induce PD-1 internalization. JS207 can inhibit VEGF-driven angiogenesis and has the property that VEGFA enhances PD-1 internalization. JS207 simultaneously binds PD-1 and VEGFA. JS207 cross-reacts with cynomolgus monkey PD-1/VEGFA and rat/mouse VEGFA, but does not bind rat/mouse PD-1. JS207 shows antitumor efficacy in mouse colon cancer and melanoma models. JS207 can be used for research related to colon cancer and melanoma.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Description
Species Reactivity
Human
In Vitro
JS207 binds human PD-1 with an EC50 of 10.4 ng/mL (58.6 pM) and is specific for related immune proteins[1].
JS207 cross-reacts with human and cynomolgus monkey PD-1 as well as human, cynomolgus monkey, rat, and mouse VEGFA[1].
JS207 (2 μg/mL) binds human PD-1 with a KD of 0.46 nM[1].
JS207 (30 nM; 0.5-4 h) induced PD-1 internalization in H293/PD-1 cells, reaching up to 65% in the presence of VEGFA[1].
JS207 (15 pM-150 nM; 5 days) promotes IL-2 and IFN-γ release in the MLR assay[1].
JS207 specifically binds to human VEGFA but does not bind to other human VEGF family proteins[1].
JS207 binds human VEGFA with a KD of 9 pM[1].
JS207 inhibits VEGFA/VEGFR2 signaling in the H293/VEGFR2 reporter gene assay with an IC50 of 0.773 nM[1].
JS207 (0.005-10 nM; 96 h) inhibits VEGFA-induced HUVEC proliferation with an IC50 of 0.296 nM[1].
JS207 can simultaneously bind to human PD-1 and human VEGFA[1].
JS207 blocks PD-1/PD-L1 in Jurkat/PD-1 and CHO/PD-L1 reporter gene assays with an EC50 of 2.89 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
JS207 (1.0-10.0 mg/kg; intraperitoneal injection; twice weekly; 6 doses total) produced dose-dependent tumor growth inhibition in the A375 melanoma NDG mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6-Pdcd1tm1(PDCD1)Bcgen/Bcgen (B-hPD-1 humanized mice)[1]
-
Dosage:0.75 mg/kg, 1.5 mg/kg, and 4.5 mg/kg
-
Administration:intraperitoneally; twice weekly; for 6 doses
-
Result:Significantly inhibited tumor growth dose-dependently at 0.75, 1.5, and 4.5 mg/kg, achieving tumor growth inhibition (TGI) rates of 76.1%, 78.0%, and 84.4%, respectively, at day 20.
-
Animal Model:NDG mice were implanted subcutaneously with A375 cells at 5×106 cells/mouse suspended and mixed with Matrigel[1]
-
Dosage:1.0 mg/kg, 3.0 mg/kg, and 10.0 mg/kg
-
Administration:intraperitoneally; twice weekly; for 6 doses
-
Result:In the saline group, the mean tumor volume reached 585 mm3 at day 21.
At 1, 3, and 10 mg/kg, mean tumor volumes were 362 mm3, 344 mm3, and 262 mm3, corresponding to TGI rates of 49.6%, 53.7%, and 72.0%, respectively.
Target
PD-1 & VEGF
Conjugated
Unconjugated
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[JS207]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)